GCG and type 2 diabetes mellitus: In our study, we used low-dose gliclazide and show augmentation of endogenous incretin response in type 2 diabetes, suggesting a potential therapeutic use and novel mechanism for low-dose sulphonylureas in patients with type 2 diabetes.